PlainRecalls
FDA Drug Moderate Class II Terminated

Auryxia (ferric citrate) tablets 210 mg, Rx Only, 200 tablets per bottle, Manufactured for and distributed by: Keryx Biopharmaceuticals, Inc., 245 First Street Suite 1400, Cambridge, MA 02142, NDC: 59922-631-01.

Reported: July 22, 2020 Initiated: July 10, 2020 #D-1389-2020

Product Description

Auryxia (ferric citrate) tablets 210 mg, Rx Only, 200 tablets per bottle, Manufactured for and distributed by: Keryx Biopharmaceuticals, Inc., 245 First Street Suite 1400, Cambridge, MA 02142, NDC: 59922-631-01.

Reason for Recall

cGMP deviations: Lots recalled were not manufactured in conformance with the FDA-approved manufacturing process for Auryxia.

Details

Units Affected
59,820 bottles
Distribution
Nationwide in the U.S.
Location
Boston, MA

Frequently Asked Questions

What product was recalled?
Auryxia (ferric citrate) tablets 210 mg, Rx Only, 200 tablets per bottle, Manufactured for and distributed by: Keryx Biopharmaceuticals, Inc., 245 First Street Suite 1400, Cambridge, MA 02142, NDC: 59922-631-01.. Recalled by Keryx Biopharmaceuticals, Inc.. Units affected: 59,820 bottles.
Why was this product recalled?
cGMP deviations: Lots recalled were not manufactured in conformance with the FDA-approved manufacturing process for Auryxia.
Which agency issued this recall?
This recall was issued by the FDA Drug on July 22, 2020. Severity: Moderate. Recall number: D-1389-2020.